Agamree (vamorolone)

The first dissociative steroid approved for DMD, designed to provide the anti-inflammatory benefits of corticosteroids while reducing the bone loss, growth stunting, and behavioral side effects that make traditional steroids difficult for boys with DMD.

Vamorolone binds to the same glucocorticoid receptors as prednisone and deflazacort but activates them differently. It suppresses the NF-kB inflammatory pathway (which drives muscle damage in DMD) without fully activating the gene transcription pathways responsible for bone loss, weight gain, and growth suppression. This 'dissociative' mechanism preserves the therapeutic anti-inflammatory effect while reducing the most problematic steroid side effects.

The most common side effects on the label were cushingoid features (a rounder face and weight gain), behavior and mood changes, vomiting, weight gain and low vitamin D, along with increased appetite, and in VISION-DMD height percentile and bone turnover markers fell on prednisone but not on vamorolone. Behavioral effects and adrenal suppression can still occur. Blood pressure and adrenal function should be monitored. Like other corticosteroids, Agamree raises the risk of infections, which can be serious or even fatal and may be harder to notice, so tell the doctor about any signs of infection. Live or live-attenuated vaccines should not be given during treatment; they should be given at least 4 to 6 weeks before starting. The label says that after more than 1 week of use the dose has to be lowered slowly rather than stopped all at once, because stopping suddenly can cause adrenal crisis. The label also warns about high blood sugar, salt and potassium changes, stomach or bowel tears, eye problems such as cataracts and glaucoma, bone loss and fractures, effects on growth and development in children, muscle weakness (myopathy), Kaposi's sarcoma, blood clots, and rare severe allergic reactions (anaphylaxis).

Taken orally once daily as a liquid suspension at 6mg/kg/day. It is best taken with a meal. The maximum daily dose is 300mg for patients who weigh more than 50kg, and doctors may lower the dose to 2mg/kg/day if needed. The label lowers the dose to 2mg/kg/day (up to 100mg) for mild to moderate liver impairment and to 4mg/kg/day (up to 200mg) with strong CYP3A4 inhibitors. Available as an oral suspension for ease of dosing in young children.

Yes, Vamorolone (Agamree) is FDA approved (2023) for the treatment of Duchenne Muscular Dystrophy.

Vamorolone is a dissociative corticosteroid, meaning it selectively activates the anti-inflammatory parts of the glucocorticoid receptor signaling pathway while reducing activation of the pathways responsible for the worst steroid side effects. Traditional steroids like prednisone and deflazacort activate both pathways equally, which is why they cause bone loss, weight gain, growth suppression, and behavioral changes. In its main trial, vamorolone improved motor function compared with placebo, and boys on it did not show the drop in height percentile or bone turnover markers seen with prednisone. It is still a corticosteroid and carries steroid warnings.

Yes, vamorolone is designed as an alternative to traditional corticosteroids for DMD. In the VISION-DMD trial it improved motor function compared with placebo, and boys on it did not show the drop in height percentile seen with prednisone. The switch should be managed by a neuromuscular specialist. The FDA label says patients can switch from prednisone or deflazacort directly, without a break or a taper first, starting at 6mg/kg/day.

The VISION-DMD Phase 2b trial compared vamorolone at 6mg/kg/day to prednisone and placebo. Compared with placebo at 24 weeks, vamorolone 6mg/kg/day improved time to stand, 6-minute walk distance, and time to run or walk 10 meters. The prednisone group was a reference, and the trial was not designed to show that vamorolone works as well as prednisone. Height percentile and bone turnover markers fell in boys on prednisone but not in boys on vamorolone. The FDA label still lists steroid warnings, including bone loss, mood and behavior changes, and adrenal suppression.

Yes. Vamorolone (Agamree) is approved for patients aged 2 and older with DMD. It comes as an oral liquid suspension, which makes dosing easy for young children. Weight-based dosing at 6mg/kg/day is taken once daily, preferably with a meal. Store unopened bottles at room temperature. After opening, keep the bottle upright in the refrigerator, and throw away any medicine left 3 months after first opening.

Some steroid-related effects can still occur, including cushingoid appearance, weight gain, increased appetite, and adrenal suppression. In VISION-DMD, boys on vamorolone did not show the fall in height percentile and bone turnover markers seen on prednisone, though the trial was not designed to compare the two, and the label still warns about bone loss and mood changes. Vamorolone is not steroid-free; it is a modified steroid designed to reduce the most problematic side effects while maintaining efficacy.